Peder S. Olofsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peder S. Olofsson has a total of 300 co-authors. Here are the top co-authors by number of shared publications:
- Laura Tarnawski
Laboratory of Immunobiology, Division of Cardiovascular Medicine, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden
9 shared publications - April Shawn Caravaca
Laboratory of Immunobiology, Center for Bioelectronic Medicine, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
6 shared publications - Alessandro L. Gallina
European Public Health Alliance
5 shared publications - Kevin J. Tracey
Institute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, Northwell Health 2 Laboratory of Biomedical Sciences Manhasset, NY
5 shared publications - Stephen G. Malin
Division of Cardiovascular Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
5 shared publications Ting Liu
Laboratory of Immunobiology, Center for Bioelectronic Medicine, Division of Cardiovascular Medicine, Department of Medicine, Solna, Center for Molecular Medicine Karolinska Institutet Stockholm Sweden
5 shared publications
Latest Publications
- Open Access
- 11 May 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1) , 73
Correction: Proliferation of activated hepatic stellate cells requires REST
- 11 May 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1) , 73
Open AccessCorrection: Proliferation of activated hepatic stellate cells requires REST
- Open Access
- 7 May 2026
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 28 (1)
Neuroimmune Dynamics in Diseases of the Arterial Wall: Mechanistic Foundations and Translational Prospects
Purpose of Review: Peripheral nerves are increasingly recognized as regulators of vascular pathology, shaping arterial tone, inflammation, and structural remodeling. This review delineates how neural circuits interface with the aortic wall, considers sympathetic and sensory pathways in atherosclerosis and aneurysm pathophysiology, and discusses emerging experimental approaches and therapeutic strategies. Recent Findings: Autonomic and sensory neural circuits are increasingly recognized as modulators of arterial disease. In experimental atherosclerosis, neuroimmune crosstalk shapes vascular inflammation and influences plaque stability. Limited available evidence from human and experimental studies suggest increased sympathetic innervation within aneurysm tissue. In preclinical models, aneurysm remodeling was linked with sympathetic input, and interventions that reduce noradrenergic signaling via sympathetic denervation or pharmacological adrenergic blockade attenuated disease severity. Improved understanding of the role for innervation in vascular pathophysiology may open therapeutic opportunities, including neuromodulation and pharmacological interventions. Clarifying sources of heterogeneity between models and clinical data can potentially refine therapeutic targets and patient selection, and advance opportunities for precision interventions. Summary: Peripheral neural circuits are integral to vascular homeostasis in health and disease, interfacing with blood vessels and regulating their physiology. Converging human and preclinical evidence implicates sympathetic innervation in disease development, and that dampening adrenergic signaling via denervation or adrenergic blockade may mitigate disease progression. This review discusses mechanistic neuroimmune crosstalk across atherosclerosis and aneurysm biology and outlines some potential translational opportunities. Together, the advances position neurovascular crosstalk as a potentially tractable axis for disease-modifying interventions.
- 7 May 2026
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 28 (1)
Open AccessNeuroimmune Dynamics in Diseases of the Arterial Wall: Mechanistic Foundations and Translational Prospects
Purpose of Review: Peripheral nerves are increasingly recognized as regulators of vascular pathology, shaping arterial tone, inflammation, and structural remodeling. This review delineates how neural circuits interface with the aortic wall, considers sympathetic and sensory pathways in atherosclerosis and aneurysm pathophysiology, and discusses emerging experimental approaches and therapeutic strategies. Recent Findings: Autonomic and sensory neural circuits are increasingly recognized as modulators of arterial disease. In experimental atherosclerosis, neuroimmune crosstalk shapes vascular inflammation and influences plaque stability. Limited available evidence from human and experimental studies suggest increased sympathetic innervation within aneurysm tissue. In preclinical models, aneurysm remodeling was linked with sympathetic input, and interventions that reduce noradrenergic signaling via sympathetic denervation or pharmacological adrenergic blockade attenuated disease severity. Improved understanding of the role for innervation in vascular pathophysiology may open therapeutic opportunities, including neuromodulation and pharmacological interventions. Clarifying sources of heterogeneity between models and clinical data can potentially refine therapeutic targets and patient selection, and advance opportunities for precision interventions. Summary: Peripheral neural circuits are integral to vascular homeostasis in health and disease, interfacing with blood vessels and regulating their physiology. Converging human and preclinical evidence implicates sympathetic innervation in disease development, and that dampening adrenergic signaling via denervation or adrenergic blockade may mitigate disease progression. This review discusses mechanistic neuroimmune crosstalk across atherosclerosis and aneurysm biology and outlines some potential translational opportunities. Together, the advances position neurovascular crosstalk as a potentially tractable axis for disease-modifying interventions.
- Open Access
- 4 April 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (7) , e71716
Lymphocyte Antigen 6G Mediates Vagotomy‐Associated Reduction in Body Weight
Dysregulation of adipocyte function is an important component of metabolic and cardiovascular diseases. It is increasingly evident that interorgan neuroimmune crosstalk in adipose tissue maintains adipose tissue functionality, yet the molecular mechanisms are incompletely understood. The vagus nerve regulates numerous physiological functions, including inflammation and weight control, even in tissues lacking direct cholinergic innervation. In this study, we examined whether vagal signaling is involved in maintaining baseline homeostasis in epididymal white adipose tissue (eWAT) by investigating how disrupting vagus signaling affects adipose tissue physiology. As expected, vagotomized male animals had lower body weight and epididymal white adipose tissue mass as compared with controls. Vagotomized animals showed increased Ly6G + cell infiltration in eWAT. Interestingly, vagotomy‐associated weight loss was significantly attenuated in neutrophil‐deficient Ly6G cre Mcl1 fl/fl mice and in mice treated with repeated injections of anti‐Ly6G antibodies. Together, these observations indicate that there is a Ly6G‐mediated vagotomy‐associated reduction in weight and reveal that Ly6G + cells participate in the regulation of eWAT energy homeostasis.
- 4 April 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (7) , e71716
Open AccessLymphocyte Antigen 6G Mediates Vagotomy‐Associated Reduction in Body Weight
Dysregulation of adipocyte function is an important component of metabolic and cardiovascular diseases. It is increasingly evident that interorgan neuroimmune crosstalk in adipose tissue maintains adipose tissue functionality, yet the molecular mechanisms are incompletely understood. The vagus nerve regulates numerous physiological functions, including inflammation and weight control, even in tissues lacking direct cholinergic innervation. In this study, we examined whether vagal signaling is involved in maintaining baseline homeostasis in epididymal white adipose tissue (eWAT) by investigating how disrupting vagus signaling affects adipose tissue physiology. As expected, vagotomized male animals had lower body weight and epididymal white adipose tissue mass as compared with controls. Vagotomized animals showed increased Ly6G + cell infiltration in eWAT. Interestingly, vagotomy‐associated weight loss was significantly attenuated in neutrophil‐deficient Ly6G cre Mcl1 fl/fl mice and in mice treated with repeated injections of anti‐Ly6G antibodies. Together, these observations indicate that there is a Ly6G‐mediated vagotomy‐associated reduction in weight and reveal that Ly6G + cells participate in the regulation of eWAT energy homeostasis.
- Open Access
- 28 January 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1)
Proliferation of activated hepatic stellate cells requires REST
Background: Activation of hepatic stellate cells (HSCs) is key in liver regeneration and the pathogenesis of chronic liver diseases, such as metabolic dysfunction-associated steatohepatitis (MASH). Activated HSCs promote liver inflammation and fibrosis which can lead to the development of liver cancer. Targeted removal of activated HSCs has shown promise in preventing liver fibrosis and liver cancer in mouse models. HSC activation is characterized by increased mitochondrial metabolism and upregulation of pro-fibrotic genes, but the underlying regulatory mechanisms remain incompletely understood. Since RE1-silencing transcription factor (REST) is known to regulate cell fate and metabolism, we investigated its involvement in HSC activation. Methods: REST-dependent mechanisms of HSC activation were studied using siRNA-mediated REST knock down in primary human HSCs and human HSC-like LX2 cells. Results: Knock down of REST in primary human HSCs and HSC-like LX2 cells reduced proliferation, promoted lipid accumulation and autophagy, and impaired mitochondrial metabolism, resulting in reduced growth. The effects were linked with REST-dependent regulation of the PI3K/AKT/mTORC1 pathway. Conclusions: Our findings identify a REST-dependent mechanism of HSC activation that is important for their activation and proliferation.
- 28 January 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1)
Open AccessProliferation of activated hepatic stellate cells requires REST
Background: Activation of hepatic stellate cells (HSCs) is key in liver regeneration and the pathogenesis of chronic liver diseases, such as metabolic dysfunction-associated steatohepatitis (MASH). Activated HSCs promote liver inflammation and fibrosis which can lead to the development of liver cancer. Targeted removal of activated HSCs has shown promise in preventing liver fibrosis and liver cancer in mouse models. HSC activation is characterized by increased mitochondrial metabolism and upregulation of pro-fibrotic genes, but the underlying regulatory mechanisms remain incompletely understood. Since RE1-silencing transcription factor (REST) is known to regulate cell fate and metabolism, we investigated its involvement in HSC activation. Methods: REST-dependent mechanisms of HSC activation were studied using siRNA-mediated REST knock down in primary human HSCs and human HSC-like LX2 cells. Results: Knock down of REST in primary human HSCs and HSC-like LX2 cells reduced proliferation, promoted lipid accumulation and autophagy, and impaired mitochondrial metabolism, resulting in reduced growth. The effects were linked with REST-dependent regulation of the PI3K/AKT/mTORC1 pathway. Conclusions: Our findings identify a REST-dependent mechanism of HSC activation that is important for their activation and proliferation.
- Open Access
- 17 December 2025
- Published by Springer Nature in Nature
- Vol. 649 (8097) , E7
Author Correction: Neuroimmune cardiovascular interfaces control atherosclerosis
- 17 December 2025
- Published by Springer Nature in Nature
- Vol. 649 (8097) , E7
Open AccessAuthor Correction: Neuroimmune cardiovascular interfaces control atherosclerosis
- Open Access
- 20 March 2025
- Published by Springer Nature in Research Square
Survival and Proliferation of Activated Hepatic Stellate Cells Requires REST
The activation of hepatic stellate cells (HSCs) is a key driver of liver fibrosis and inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). Targeting activated HSCs has shown promise in preventing liver fibrosis and cancer in mouse models. HSC activation is characterized by increased mitochondrial metabolism and upregulation of pro-fibrotic genes. Since RE1-silencing transcription factor (REST) is known to regulate cell fate, metabolism, and survival, we investigated its involvement in HSC activation. We observed reduced Rest mRNA levels in mouse activated HSCs as compared with mouse quiescent HSCs. In primary human HSCs and HSC-like LX2 cells, REST knock-down led to decreased expression of pro-fibrogenic markers and was essential for the survival and proliferation of activated human HSCs in vitro . REST knock-down also promoted lipid accumulation, impaired mitochondrial metabolism, and increased AMPK phosphorylation and autophagy, resulting in reduced growth. Our findings identify a REST-dependent mechanism of HSC activation that is important for their survival and proliferation.
- 20 March 2025
- Published by Springer Nature in Research Square
Open AccessSurvival and Proliferation of Activated Hepatic Stellate Cells Requires REST
The activation of hepatic stellate cells (HSCs) is a key driver of liver fibrosis and inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). Targeting activated HSCs has shown promise in preventing liver fibrosis and cancer in mouse models. HSC activation is characterized by increased mitochondrial metabolism and upregulation of pro-fibrotic genes. Since RE1-silencing transcription factor (REST) is known to regulate cell fate, metabolism, and survival, we investigated its involvement in HSC activation. We observed reduced Rest mRNA levels in mouse activated HSCs as compared with mouse quiescent HSCs. In primary human HSCs and HSC-like LX2 cells, REST knock-down led to decreased expression of pro-fibrogenic markers and was essential for the survival and proliferation of activated human HSCs in vitro . REST knock-down also promoted lipid accumulation, impaired mitochondrial metabolism, and increased AMPK phosphorylation and autophagy, resulting in reduced growth. Our findings identify a REST-dependent mechanism of HSC activation that is important for their survival and proliferation.
- Open Access
- 19 November 2024
- Published by Wiley in Journal of Internal Medicine
- Vol. 297 (1) , 47-59
Statin‐associated regulation of hepatic PNPLA3 in patients without known liver disease
Background and objectives: Statins are used for metabolic dysfunction‐associated steatotic liver disease (MASLD) (NAFLD) treatment, but their role in this context is unclear. Genetic variants of patatin‐like phospholipase domain containing 3 (PNPLA3) are associated with MASLD susceptibility and statin treatment efficacy. Access to liver biopsies before established MASLD is limited, and statins and PNPLA3 in early liver steatosis are thus difficult to study.Methods: Liver biopsies were collected from 261 patients without known liver disease at surgery and stratified based on statin use and criteria for the metabolic syndrome (MS). Genotypes and transcript levels were measured using Illumina and Affymetrix arrays, and metabolic and lipoprotein profiles by clinical assays. Statin effects on PNPLA3, de novo lipogenesis (DNL), and lipid accumulation were further studied in vitro.Results: The PNPLA3I148M genetic variant was associated with significantly lower hepatic levels of cholesterol synthesis‐associated transcripts. Patients with MS had significantly higher hepatic levels of MASLD and lipogenesis‐associated transcripts than non‐MS patients. Patients with MS on statin therapy had significantly higher hepatic levels of PNPLA3, acetyl‐CoA carboxylase alpha, and ATP citrate lyase, and statin use was associated with higher plasma fasting glucose, insulin, and HbA1c. Exposure of hepatocyte‐like HepG2 cells to atorvastatin promoted intracellular accumulation of triglycerides and lipogenesis‐associated transcripts. Atorvastatin‐exposure of HepG2, sterol O‐acyltransferase (SOAT) 2‐only‐HepG2, primary human hepatic stellate, and hepatic stellate cell‐like LX2 cells significantly increased levels of PNPLA3 and SREBF2‐target genes, whereas knockdown of SREBF2 attenuated this effect.Conclusions: Collectively, these observations suggest statin‐associated regulation of PNPLA3 and DNL in liver. The potential interaction between PNPLA3 genotype and metabolic status should be considered in future studies in the context of statin therapy for MASLD.
- 19 November 2024
- Published by Wiley in Journal of Internal Medicine
- Vol. 297 (1) , 47-59
Open AccessStatin‐associated regulation of hepatic PNPLA3 in patients without known liver disease
Background and objectives: Statins are used for metabolic dysfunction‐associated steatotic liver disease (MASLD) (NAFLD) treatment, but their role in this context is unclear. Genetic variants of patatin‐like phospholipase domain containing 3 (PNPLA3) are associated with MASLD susceptibility and statin treatment efficacy. Access to liver biopsies before established MASLD is limited, and statins and PNPLA3 in early liver steatosis are thus difficult to study.Methods: Liver biopsies were collected from 261 patients without known liver disease at surgery and stratified based on statin use and criteria for the metabolic syndrome (MS). Genotypes and transcript levels were measured using Illumina and Affymetrix arrays, and metabolic and lipoprotein profiles by clinical assays. Statin effects on PNPLA3, de novo lipogenesis (DNL), and lipid accumulation were further studied in vitro.Results: The PNPLA3I148M genetic variant was associated with significantly lower hepatic levels of cholesterol synthesis‐associated transcripts. Patients with MS had significantly higher hepatic levels of MASLD and lipogenesis‐associated transcripts than non‐MS patients. Patients with MS on statin therapy had significantly higher hepatic levels of PNPLA3, acetyl‐CoA carboxylase alpha, and ATP citrate lyase, and statin use was associated with higher plasma fasting glucose, insulin, and HbA1c. Exposure of hepatocyte‐like HepG2 cells to atorvastatin promoted intracellular accumulation of triglycerides and lipogenesis‐associated transcripts. Atorvastatin‐exposure of HepG2, sterol O‐acyltransferase (SOAT) 2‐only‐HepG2, primary human hepatic stellate, and hepatic stellate cell‐like LX2 cells significantly increased levels of PNPLA3 and SREBF2‐target genes, whereas knockdown of SREBF2 attenuated this effect.Conclusions: Collectively, these observations suggest statin‐associated regulation of PNPLA3 and DNL in liver. The potential interaction between PNPLA3 genotype and metabolic status should be considered in future studies in the context of statin therapy for MASLD.
- Open Access
- 12 September 2024
- Published by Elsevier in Current Opinion in Endocrine and Metabolic Research
- Vol. 37
Cholinergic signaling in adipose tissue
- 12 September 2024
- Published by Elsevier in Current Opinion in Endocrine and Metabolic Research
- Vol. 37
Open AccessCholinergic signaling in adipose tissue
- Open Access
- 11 March 2024
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 3 (3) , 356-371
Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult
Apolipoprotein-B (APOB)-containing lipoproteins cause atherosclerosis. Whether the vasculature is the initially responding site or if atherogenic dyslipidemia affects other organs simultaneously is unknown. Here we show that the liver responds to a dyslipidemic insult based on inducible models of familial hypercholesterolemia and APOB tracing. An acute transition to atherogenic APOB lipoprotein levels resulted in uptake by Kupffer cells and rapid accumulation of triglycerides and cholesterol in the liver. Bulk and single-cell RNA sequencing revealed a Kupffer-cell-specific transcriptional program that was not activated by a high-fat diet alone or detected in standard liver function or pathological assays, even in the presence of fulminant atherosclerosis. Depletion of Kupffer cells altered the dynamic of plasma and liver lipid concentrations, indicating that these liver macrophages help restrain and buffer atherogenic lipoproteins while simultaneously secreting atherosclerosis-modulating factors into plasma. Our results place Kupffer cells as key sentinels in organizing systemic responses to lipoproteins at the initiation of atherosclerosis.
- 11 March 2024
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 3 (3) , 356-371
Open AccessKupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult
Apolipoprotein-B (APOB)-containing lipoproteins cause atherosclerosis. Whether the vasculature is the initially responding site or if atherogenic dyslipidemia affects other organs simultaneously is unknown. Here we show that the liver responds to a dyslipidemic insult based on inducible models of familial hypercholesterolemia and APOB tracing. An acute transition to atherogenic APOB lipoprotein levels resulted in uptake by Kupffer cells and rapid accumulation of triglycerides and cholesterol in the liver. Bulk and single-cell RNA sequencing revealed a Kupffer-cell-specific transcriptional program that was not activated by a high-fat diet alone or detected in standard liver function or pathological assays, even in the presence of fulminant atherosclerosis. Depletion of Kupffer cells altered the dynamic of plasma and liver lipid concentrations, indicating that these liver macrophages help restrain and buffer atherogenic lipoproteins while simultaneously secreting atherosclerosis-modulating factors into plasma. Our results place Kupffer cells as key sentinels in organizing systemic responses to lipoproteins at the initiation of atherosclerosis.
- Open Access
- 31 March 2023
- Published by Springer Nature in Bioelectronic Medicine
- Vol. 9 (1) , 1-10
Hepatic stellate cell activation markers are regulated by the vagus nerve in systemic inflammation
Background: The liver is an important immunological organ and liver inflammation is part of the pathophysiology of non-alcoholic steatohepatitis, a condition that may promote cirrhosis, liver cancer, liver failure, and cardiovascular disease. Despite dense innervation of the liver parenchyma, little is known about neural regulation of liver function in inflammation. Here, we study vagus nerve control of the liver response to acute inflammation. Methods: Male C57BL/6 J mice were subjected to either sham surgery, surgical vagotomy, or electrical vagus nerve stimulation followed by intraperitoneal injection of the TLR2 agonist zymosan. Animals were euthanized and tissues collected 12 h after injection. Samples were analyzed by qPCR, RNAseq, flow cytometry, or ELISA. Results: Hepatic mRNA levels of pro-inflammatory mediators Ccl2, Il-1β, and Tnf-α were significantly higher in vagotomized mice compared with mice subjected to sham surgery. Differences in liver Ccl2 levels between treatment groups were largely reflected in the plasma chemokine (C–C motif) ligand 2 (CCL2) concentration. In line with this, we observed a higher number of macrophages in the livers of vagotomized mice compared with sham as measured by flow cytometry. In mice subjected to electrical vagus nerve stimulation, hepatic mRNA levels of Ccl2, Il1β, and Tnf-α, and plasma CCL2 levels, were significantly lower compared with sham. Interestingly, RNAseq revealed that a key activation marker for hepatic stellate cells (HSC), Pnpla3, was the most significantly differentially expressed gene between vagotomized and sham mice. Of note, several HSC-activation associated transcripts were higher in vagotomized mice, suggesting that signals in the vagus nerve contribute to HSC activation. In support of this, we observed significantly higher number of activated HSCs in vagotomized mice as compared with sham as measured by flow cytometry. Conclusions: Signals in the cervical vagus nerve controlled hepatic inflammation and markers of HSC activation in zymosan-induced peritonitis.
- 31 March 2023
- Published by Springer Nature in Bioelectronic Medicine
- Vol. 9 (1) , 1-10
Open AccessHepatic stellate cell activation markers are regulated by the vagus nerve in systemic inflammation
Background: The liver is an important immunological organ and liver inflammation is part of the pathophysiology of non-alcoholic steatohepatitis, a condition that may promote cirrhosis, liver cancer, liver failure, and cardiovascular disease. Despite dense innervation of the liver parenchyma, little is known about neural regulation of liver function in inflammation. Here, we study vagus nerve control of the liver response to acute inflammation. Methods: Male C57BL/6 J mice were subjected to either sham surgery, surgical vagotomy, or electrical vagus nerve stimulation followed by intraperitoneal injection of the TLR2 agonist zymosan. Animals were euthanized and tissues collected 12 h after injection. Samples were analyzed by qPCR, RNAseq, flow cytometry, or ELISA. Results: Hepatic mRNA levels of pro-inflammatory mediators Ccl2, Il-1β, and Tnf-α were significantly higher in vagotomized mice compared with mice subjected to sham surgery. Differences in liver Ccl2 levels between treatment groups were largely reflected in the plasma chemokine (C–C motif) ligand 2 (CCL2) concentration. In line with this, we observed a higher number of macrophages in the livers of vagotomized mice compared with sham as measured by flow cytometry. In mice subjected to electrical vagus nerve stimulation, hepatic mRNA levels of Ccl2, Il1β, and Tnf-α, and plasma CCL2 levels, were significantly lower compared with sham. Interestingly, RNAseq revealed that a key activation marker for hepatic stellate cells (HSC), Pnpla3, was the most significantly differentially expressed gene between vagotomized and sham mice. Of note, several HSC-activation associated transcripts were higher in vagotomized mice, suggesting that signals in the vagus nerve contribute to HSC activation. In support of this, we observed significantly higher number of activated HSCs in vagotomized mice as compared with sham as measured by flow cytometry. Conclusions: Signals in the cervical vagus nerve controlled hepatic inflammation and markers of HSC activation in zymosan-induced peritonitis.